Company Dossier · Health Care
Humana
- S&P 500
- Russell 1000
What Humana is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to March 31, 2026: $137 billion, up 14% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to March 31, 2026: $1.27 billion, down 47% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to March 31, 2026: $0.57 billion, up 16% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.15 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $1.48 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 29, 2026): sentiment 0.40 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 1 lowered, 3 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 19, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q1 2026: $0.1 million on the open market.SEC Form 4
- 930 institutional managers reported a position at June 30, 2026 (+141 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 112 (88 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Humana is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding ↔ Retrenching
Withheld: 50% of the evidence is readable at this date (needs 60%).
- Capital spending—
- Debt raised—
- Buybacks vs capex—
- Hiring filings74th pct
- Deals and private raises49th pct
- Patent publications97th pct
Confident ↔ Hedging
Mixed
- Call sentiment60th pct
- Call confidence53rd pct
- Guidance changes22nd pct
- Risk factors added73rd pct
- Insider open-market trades—
- − Guidance changes
- + Risk factors added
- + Call sentiment
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver45th pct
- Stress filings48th pct
Credit
How these are built →Humana's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$14.0B
- Due within a year $1.7B
- Longer term $12.3B
- Default point $7.9B (short + ½ long)
Finance leases included · Mar 31, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Mar 26, 2025 | $250M | 5.375% | 2031 (6y) | +130bp | 5.386% |
| Mar 3, 2025 | $750M | 5.550% | 2035 (10y) | +138bp | 5.563% |
| Mar 3, 2025 | $500M | 6.000% | 2055 (30y) | +160bp | 6.075% |
| Mar 11, 2024 | $1B | 5.750% | 2054 (30y) | +147bp | 5.753% |
| Mar 11, 2024 | $1.25B | 5.375% | 2031 (7y) | +127bp | 5.384% |
| Nov 2, 2023 | $500M | 5.750% | 2028 (5y) | +115bp | 5.788% |
| Nov 2, 2023 | $850M | 5.950% | 2034 (10y) | +147bp | 6.146% |
From the pricing term sheets Humana filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Humana: earnings call confidence
Palanor Discourse score per call, 0 to 1
Hiring and ownership
In the news
Headlines that name Humana, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralHumana Stock: Star Ratings Progress Doesn’t Erase Valuation Concerns (NYSE:HUM)
seekingalpha.com · via Marketaux · Oct 11, 2026
- NeutralHumana Surges On 2027 CMS Ratings, Technical Breakout, Shares Fairly Priced (NYSE:HUM)
seekingalpha.com · via Marketaux · Oct 9, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (RESOLUTION PUBLIC AFFAIRS, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ALB SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)third_quarter 2026 · $0.1 million
- Oct 20, 2026Patent
- Oct 19, 2026LobbyingLobbying report (HUMANA, INC.)third_quarter 2026 · $1.5 million
- Oct 18, 2026LobbyingLobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
- Oct 16, 2026LobbyingLobbying report (S-3 GROUP)third_quarter 2026 · $0.1 million
- Oct 6, 2026Patent
- Sep 28, 2026Federal awardFederal award from Department of Veterans Affairs$23.2 million
- Sep 21, 2026Trademark
- Sep 1, 2026Patent
- Aug 18, 2026Patent
- Aug 11, 2026Patent
- Jul 29, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (HUMANA, INC.)second_quarter 2026 · $0.4 million
- Jul 20, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)second_quarter 2026 · $0.1 million
- Jul 1, 2026Trademark
- Jul 1, 2026Trademark
- Jul 1, 2026Trademark
- Jul 1, 2026Trademark
- May 19, 20268-KMaterial agreement signedItem 1.01
- Apr 20, 20268-KShareholder vote resultsItem 5.07
- Apr 10, 20268-KDirector or officer changeItem 5.02
- Mar 9, 20268-KMaterial agreement signedItem 1.01
- Feb 19, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Dec 16, 20258-KDirector or officer changeItem 5.02
- May 30, 20258-KMaterial agreement signedItem 1.01
- Apr 18, 20258-KShareholder vote resultsItem 5.07
- Mar 31, 20258-KMaterial agreement signedItem 1.01
- Mar 5, 20258-KMaterial agreement signedItem 1.01
- Feb 20, 202510-KAnnual report (10-K)1 risk factors added, 0 removed
- Dec 3, 20248-KDirector or officer changeItem 5.02
- Oct 23, 20248-KDirector or officer changeItem 5.02
- Feb 15, 202410-KAnnual report (10-K)0 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Centene Corporation CNC | $179B | $8.9B | Jun 30, 2026 |
| Elevance Health ELV | $201B | $6.3B | Jun 30, 2026 |
| Molina Healthcare MOH | $44.5B | −$0.6B | Jun 30, 2026 |
| Johnson & Johnson JNJ | $97.9B | $22.2B | Jun 28, 2026 |
| Eli Lilly and Company LLY | $79.7B | — | Jun 30, 2026 |
| Cardinal Health CAH | $245B | $5.5B | Dec 31, 2025 |
| HCA Healthcare HCA | $76.4B | $7.9B | Mar 31, 2026 |
| Cigna CI | $282B | — | Jun 30, 2026 |